Table 1 Baseline characteristics of patients
Characteristic | Value |
|---|---|
Sex | |
Male | 69 (92.0) |
Female | 6 (8.0) |
Age, median (range, years) | 50 (29–72) |
Bodyweight (range, kg) | 60 (35–91) |
Radiographic liver cirrhosis | 38 (50.7) |
Hepatitis etiology | |
Hepatitis B virus | 66 (88.0) |
Hepatitis C virus | 3 (4.0) |
Other | 7 (9.3) |
ECOG PS | |
0 | 18 (24.0) |
1 | 56 (74.7) |
2 | 1 (1.3) |
Child–Pugh score | |
7 | 59 (78.7) |
8 | 13 (17.3) |
9 | 3 (4.0) |
ALBI score | -1.740 ± 0.36 |
ALBI grade | |
2 | 59 (78.7) |
3 | 16 (21.3) |
Alpha fetoprotein, ≥ 400 ng/ml | |
Yes | 37 (49.3) |
No | 38 (50.7) |
Total bilirubin (μmol/L) | 24.81 ± 21.36 |
Albumin (g/L) | 30.22 ± 3.37 |
PT (sec) | 13.35 ± 1.65 |
AST (U/L) | 89.37 ± 120.78 |
ALT (U/L) | 60.13 ± 69.90 |
ALP (U/L) | 176.64 ± 105.56 |
Max tumor size (cm) | 8.39 ± 5.06 |
Tumor number | |
< 3 | 36 (48.0) |
≥ 3 | 39 (52.0) |
Macrovascular invasion | |
Yes | 53 (70.7) |
No | 22 (29.3) |
Extrahepatic metastasis | |
Yes | 35 (46.7) |
No | 40 (53.3) |
BCLC stage | |
A | 6 (8.0) |
B | 2 (2.7) |
C | 67 (89.3) |
Total dose (Gy) | 53.33 ± 7.08 |
Dose per fraction (Gy) | 2.96 ± 0.84 |
GTV (cc/ml) | 749.23 ± 729.88 |
EQ D28 (Gy) | 59.23 ± 10.42 |
NLV (cc/ml) | 911.56 ± 269.88 |
Dmean (Gy) | 17.54 ± 5.26 |
Prior treatment | |
TACE | 56 (74.7) |
RFA | 6 (8.0) |
Surgical resection | 26 (34.7) |
Systemic therapy | 18 (24.0) |